ReviewViruses2015
Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma.
Review in Viruses, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Melphalan improves toxicity of arsenic trioxide in adult T-cell leukemia/lymphoma cells.Biochemistry and biophysics reports · 2025Article
- Apigenin improves cytotoxicity of antiretroviral drugs against HTLV-1 infected cells through the modulation of AhR signaling.NeuroImmune pharmacology and therapeutics · 2023Article
- Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma-Romanian Experience.Journal of clinical medicine · 2020Article
- Mouse model recapitulates the phenotypic heterogeneity of human adult T-cell leukemia/lymphoma in bone.Journal of bone oncology · 2019Article
- Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas.International journal of medical sciences · 2019Review
- Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma.Cancer cell · 2018Article
- Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review.Current hematologic malignancy reports · 2018Review
- Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma.Frontiers in microbiology · 2018Review
- Viral Oncology: Molecular Biology and Pathogenesis.Journal of clinical medicine · 2017Review
- Human T-cell lymphotropic virus type 1 and its oncogenesis.Acta pharmacologica Sinica · 2017Review
- HTLV-1 Tax upregulates early growth response protein 1 through nuclear factor-κB signaling.Oncotarget · 2017Article
- Extranodal Non-Hodgkin's Lymphoma of the Oral Cavity: A Case Report.Iranian journal of medical sciences · 2017Article
- Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α.Blood advances · 2017Article
- Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma.Clinical medicine insights. Blood disorders · 2017Article
- [Clinical characteristics and prognosis in 12 patients with adult T cell leukemia/lymphoma confirmed by HTLV-1 provirus gene detection].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Peripheral lymphocytosis presenting as EBV/HTLV-1 co-infection adult T-cell leukemia.Hematology, transfusion and cell therapyArticle
- Article
- Adult T-cell leukemia/lymphoma treatment in Bahia, Brazil.Revista brasileira de hematologia e hemoterapiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by human T-cell leukemia/lymphoma virus type 1 (HTLV-1). ATLL occurs in approximately 3%-5% of HTLV-1 carriers during their lifetime and follows a heterogeneous clinical course. The Shimoyama classification has been frequently used for treatment decisions in ATLL patients, and antiviral therapy has been reportedly promising, particularly in patients with indolent type ATLL; however, the prognosis continues to be dismal for patients with aggressive-type ATLL. Recent efforts to improve treatment outcomes have been focused on the development of prognostic stratification and improved dosage, timing, and combination of therapeutic modalities, such as antiviral therapy, chemotherapy, allogeneic hematopoietic stem cell transplantation, and molecular targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.